An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality. // Molecular Therapy: Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S2950329926001657?dgcid=rss_sd_all
An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality. Molecular Therapy: Oncology. https://www.sciencedirect.com/science/article/pii/S2950329926001657?dgcid=rss_sd_all
“An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality.” Molecular Therapy: Oncology.
@article{article59369,
title = {An engineered PD-1 receptor-based CAR that binds anti-PD-1 antibodies but not PD-L1 to enhance T-cell functionality},
journal = {Molecular Therapy: Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S2950329926001657?dgcid=rss_sd_all}
}